Article

Gains in lung cancer

As attention moves to lung cancer this month, I wanted to share the infographic below. It highlights current research into lung cancer and shows, among other points, that lung cancer is no longer one disease. A few years ago, I was attending the annual meeting of ASCO (the professional oncology organization), which showcases studies that will change clinical practice and future research. Scientists were discussing the gains a new treatment had made in that it targets about 10 percent of non-small cell lung cancers. While some people questioned the importance of a treatment that only works in a small group of patients, the researchers were quick to note that 10 percent of patients diagnosed with lung cancer in a year is still more people affected than all those diagnosed with Hodgkin lymphoma in a year (actually, it's more than double). It's the number one cancer killer and a stigma of blame has hindered awareness and research funding. Add to that the absolute complexity of the disease, and it makes for a tough cancer to crack. Fortunately, research is beginning to make small gains in this hard-to-treat cancer. Advocacy organizations are increasing awareness and funding. Lung cancer survivors are raising their voices to help remove the stigma of the disease.We have a long way to go, but I'm confident we're on the right track.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Waldenstrom macroglobulinemia is often slow growing, with high survival but lower quality of life over time, explained researcher Alisha Kimble.
Image of woman.
Image of two doctors and text.
Combining JNJ-1900 with Keytruda may improve distant control of lung cancer, explained by Dr. Jared Weiss.
image of serzan.
Dr. Breelyn Wilky explains that personalized treatments are helping improve outcomes for patients with gastrointestinal stromal tumors.
Image of two doctors with text.
Image of doctors with text.
Imiage of two doctors with text.
Treatment with zanzalintinib plus Opdivo and Opdualag is an option worth exploring in patients with previously untreated clear cell renal cell carcinoma
Related Content